KRMD vs. BWAY, ALUR, BLUA, TELA, STIM, NVNO, SEPA, MGRM, SRTS, and PDEX
Should you be buying KORU Medical Systems stock or one of its competitors? The main competitors of KORU Medical Systems include BrainsWay (BWAY), Allurion Technologies (ALUR), BlueRiver Acquisition (BLUA), TELA Bio (TELA), Neuronetics (STIM), enVVeno Medical (NVNO), SEP Acquisition (SEPA), Monogram Orthopaedics (MGRM), Sensus Healthcare (SRTS), and Pro-Dex (PDEX). These companies are all part of the "surgical & medical instruments" industry.
KORU Medical Systems (NASDAQ:KRMD) and BrainsWay (NASDAQ:BWAY) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, community ranking, dividends, earnings and risk.
BrainsWay has a net margin of -4.83% compared to KORU Medical Systems' net margin of -45.24%. BrainsWay's return on equity of -3.98% beat KORU Medical Systems' return on equity.
KORU Medical Systems has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, BrainsWay has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500.
58.6% of KORU Medical Systems shares are held by institutional investors. Comparatively, 30.1% of BrainsWay shares are held by institutional investors. 25.6% of KORU Medical Systems shares are held by insiders. Comparatively, 19.0% of BrainsWay shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, BrainsWay had 4 more articles in the media than KORU Medical Systems. MarketBeat recorded 5 mentions for BrainsWay and 1 mentions for KORU Medical Systems. KORU Medical Systems' average media sentiment score of 1.94 beat BrainsWay's score of 0.70 indicating that KORU Medical Systems is being referred to more favorably in the media.
KORU Medical Systems currently has a consensus target price of $3.50, indicating a potential upside of 53.51%. BrainsWay has a consensus target price of $13.00, indicating a potential upside of 141.64%. Given BrainsWay's higher possible upside, analysts plainly believe BrainsWay is more favorable than KORU Medical Systems.
BrainsWay has higher revenue and earnings than KORU Medical Systems. BrainsWay is trading at a lower price-to-earnings ratio than KORU Medical Systems, indicating that it is currently the more affordable of the two stocks.
BrainsWay received 26 more outperform votes than KORU Medical Systems when rated by MarketBeat users. Likewise, 64.58% of users gave BrainsWay an outperform vote while only 60.00% of users gave KORU Medical Systems an outperform vote.
Summary
BrainsWay beats KORU Medical Systems on 11 of the 18 factors compared between the two stocks.
Get KORU Medical Systems News Delivered to You Automatically
Sign up to receive the latest news and ratings for KRMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
KORU Medical Systems Competitors List
Related Companies and Tools
